Glenmede Trust Co. NA Has $1.05 Million Holdings in Dianthus Therapeutics, Inc. $DNTH

Glenmede Trust Co. NA raised its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 96.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,470 shares of the company’s stock after purchasing an additional 6,125 shares during the period. Glenmede Trust Co. NA’s holdings in Dianthus Therapeutics were worth $1,046,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of DNTH. First Horizon Corp bought a new position in shares of Dianthus Therapeutics during the 1st quarter worth about $32,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at about $40,000. Raymond James Financial Inc. bought a new stake in shares of Dianthus Therapeutics in the second quarter valued at about $27,000. Russell Investments Group Ltd. acquired a new stake in Dianthus Therapeutics during the third quarter worth about $64,000. Finally, ABS Direct Equity Fund LLC acquired a new stake in Dianthus Therapeutics during the first quarter worth about $179,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

DNTH has been the subject of several recent research reports. Wedbush upped their price target on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Friday, July 17th. Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Truist Financial raised their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $124.27.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 26,530 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the transaction, the executive vice president directly owned 4,000 shares in the company, valued at $362,480. This represents a 86.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Ryan Savitz sold 31,249 shares of Dianthus Therapeutics stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total value of $3,157,086.47. Following the transaction, the executive vice president directly owned 31,249 shares of the company’s stock, valued at approximately $3,157,086.47. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 87,779 shares of company stock worth $7,985,235 over the last three months. Company insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Trading Down 2.3%

NASDAQ DNTH opened at $109.92 on Friday. The stock’s 50 day moving average is $94.40 and its two-hundred day moving average is $80.45. The company has a market capitalization of $6.01 billion, a price-to-earnings ratio of -26.49 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 1-year low of $18.08 and a 1-year high of $114.55.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The company had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. On average, analysts predict that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.